What Actinium Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 8 | 8 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 2,297,674 | 2,297,674 |
| Disposed | 0 | 0 |
| Net activity | +2,297,674 | +2,297,674 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| David Matthew T | Chief Financial Officer | Oct 14 | Grant / award · A | +250,000 | — | — | 250,000 |
| Chell Jeffrey W. | Director | Sep 02 | Grant / award · A | +61,600 | — | — | 61,600 |
| Steinhart Richard I | Director | Sep 02 | Grant / award · A | +62,800 | — | — | 63,116 |
| Seth Sandesh | Chief Executive Officer | Sep 02 | Grant / award · A | +1,027,274 | — | — | 1,965,355 |
| Seth Sandesh | Chief Executive Officer | Sep 02 | Grant / award · A | +753,600 | — | — | 938,081 |
| Nicholson, C. David | Director | Sep 02 | Grant / award · A | +62,800 | — | — | 63,300 |
| Almenoff June Sherie | Director | Sep 02 | Grant / award · A | +18,000 | — | — | 18,000 |
| Shetty Ajit | Director | Sep 02 | Grant / award · A | +61,600 | — | — | 62,357 |
| Seth Sandesh | Chief Executive Officer | Aug 18 | Withheld — tax / exercise cost · F | −120,900 | $1.71 | −$207K | 184,481 |
| Seth Sandesh | Chief Executive Officer | Aug 17 | Grant / award · A | +300,000 | — | — | 305,381 |
| Berger Mark Stanley | Chief Medical Officer | Mar 05 | In/At-money Exercise · X | +3,500 | $0.60 | +$2.1K | 22,500 |
| Seth Sandesh | Chairman & CEO | Feb 21 | In/At-money Exercise · X | +8,125 | $0.60 | +$4.88K | 161,458 |
| Seth Sandesh | Chairman & CEO | Dec 10 | Open-market buy · P | +10,000 | $0.44 | +$4.37K | 153,333 |
| O'Loughlin Steve | Principal Financial Officer | Dec 10 | Open-market buy · P | +10,000 | $0.44 | +$4.35K | 35,500 |
| Ludwig Dale L. | Chief Scientific Officer | Nov 19 | Open-market buy · P | +10,000 | $0.45 | +$4.5K | 10,000 |
| Seth Sandesh | CEO | Jul 17 | Open-market buy · P | +10,000 | $0.79 | +$7.9K | 143,333 |
| O'Loughlin Steve | Principal Financial Officer | Jun 15 | Open-market buy · P | +12,000 | $0.50 | +$6K | 25,500 |
| Seth Sandesh | Chairman & CEO | Apr 19 | Open-market buy · P | +5,000 | $0.38 | +$1.9K | 133,333 |
| Steinhart Richard I | Director | Mar 06 | Other Transaction · J | +7,000 | $0.50 | +$3.5K | 9,500 |
| Berger Mark Stanley | Chief Medical Officer | Mar 06 | Other Transaction · J | +14,000 | $0.50 | +$7K | 19,000 |
Loading...
